Last edited: October 30, 2026
A urothelial papilloma is a rare benign growth of the urinary tract mucosa. The diagnosis must be distinguished from other papillary lesions through histological examination. Therefore, a „papillary tumor“ visible during cystoscopy is not automatically a confirmed papilloma.[1,2]
As Herbert Eder I explain the progression from blood in the urine through biopsy to the appropriate follow-up plan. Inverted growth does not in itself indicate malignancy, but it does require a precise pathological classification. Also Frequency therapy cannot make this distinction. Further treatment should be based on the complete findings and not solely on a tumor name that is reassuring or alarming.
How a papilloma appears in the tissue
The urothelium lines the urinary tract. A typical papilloma grows with fine, branched projections toward the lumen. In an inverted papilloma, the cell clusters extend predominantly inward beneath the surface. This direction of growth alone does not indicate malignancy. The decisive factors are an orderly tissue structure and cells that are largely unremarkable. Urothelial carcinoma can also grow inward, which is why the term „inverted“ does not in itself rule out malignancy without a precise histological classification. A simple count of cell layers does not replace this assessment. [2]
The term „papilloma“ should therefore not be based solely on the appearance observed during endoscopy. Ask for the final findings and inquire whether the diagnosis is definitive, whether the lesion has been completely removed, and whether there are any other findings present. These three pieces of information are more useful for further planning than the size alone.
Blood in the urine should be investigated
One possible reason for the examination is blood in the urine, even if there is no pain. It may be visible or only detected during a urinalysis. There are various possible causes, including infections, stones, changes in the kidneys or prostate, and tumors. The presence of blood, therefore, does not indicate either a papilloma or cancer. The initial evaluation includes a medical history, a physical examination, and an appropriate urinalysis. Sometimes a sample must be retested, for example, if contamination with menstrual blood is a possibility. [3]
Please describe when the discoloration began, whether you noticed any blood clots, and whether you experienced any pain, fever, or difficulty urinating. List any previous urological conditions and all medications you are taking. Even if your urine now looks normal again, this medical history is important for your appointment. If you took a photo of the discoloration, it can supplement your description; however, it is not a substitute for an examination.
The Role of Cystoscopy
During a cystoscopy, a thin optical instrument is inserted through the urethra into the bladder. This allows the urologist to directly examine the mucous membrane and identify any abnormal areas. A purely diagnostic procedure can often be performed under local anesthesia. For a Tissue removal or more extensive treatment, other anesthesia techniques may be necessary. If a lesion in the ureter or renal pelvis is suspected, a targeted examination of the upper urinary tract is required; a ureteroscopy may be used for this purpose. [4]
Additional blood tests or imaging of the urinary tract can help identify other causes of bleeding. A CT For example, it can visualize the urinary tract; blood test results can provide clues about kidney disease. Ordering such a test does not automatically mean that a benign papilloma has already metastasized. Ask about the specific clinical question being addressed and how the result would influence further treatment. Not every test is equally necessary in every situation. [3]
The examination of cells shed into the urine—known as cytology—is particularly helpful in detecting high-grade tumors. However, a normal result does not rule out the possibility of a neoplasm. In cases of suspicious visual findings, a urinary marker does not replace cystoscopy and tissue examination. Additional imaging depends on the clinical question and the possible involvement of the urinary tract. [5]
Why Pathologists Sometimes Need to Take a Closer Look
Inverted papillomas, in particular, can be difficult to distinguish from other urothelial lesions in small or damaged specimens. A recent review article from 2026 emphasizes the importance of the entire tissue specimen. Additional staining techniques can be helpful but do not reliably resolve every borderline case. In cases of uncertainty, a second opinion from an experienced uropathology laboratory may be advisable. This is particularly relevant if there is a history of tumors or if the diagnosis does not match what was observed during endoscopy. The planned treatment should take this uncertainty into account. [6]
Molecular research supports the distinct nature of inverted papilloma. In a study of 39 such tumors, alterations in genes of the RAS family were frequently found; several alterations typical of urothelial carcinomas were absent. No recurrences or development of carcinoma were observed during the follow-up period. The study aids in understanding the disease, but a single genetic finding does not yet constitute a universally valid diagnostic test. For specific clinical management, the combination of tissue analysis, medical history, and clinical findings remains decisive. [7]
How to Remove the Change
If a bladder lesion is detected, it is usually removed endoscopically through the urethra. During a transurethral resection, the growth is removed with an instrument, bleeding is controlled, and the tissue is examined. The procedure is usually performed under general anesthesia or spinal anesthesia. A urinary catheter may be required temporarily, sometimes with irrigation. Discuss any medications you are taking beforehand—especially anticoagulants—and ask what restrictions will apply to you after the procedure. [8]
For a clearly diagnosed, completely removed inverted papilloma, local resection is usually sufficient. The diagnosis alone does not warrant radiation therapy, systemic chemotherapy, or removal of the entire bladder. If such more extensive treatment is considered, it must be determined whether there is in fact another or additional Tumor is present. That is precisely why a treatment recommendation should be based on the complete pathology report and not just on the term „bladder tumor.“. [6]
What the Long-Term Data Reveal
In a study published in 2014 involving 41 primary urothelial papillomas, only a few recurrent papillomas or subsequent new lesions with low malignant potential were observed after an average of just under seven years. A very early recurrence was interpreted as likely resulting from incomplete initial removal. These favorable results pertained to strictly defined diagnoses without prior or concurrent carcinoma. They justify a reassuring prognosis but do not provide a blanket guarantee that every future bladder finding will also be benign. [9]
An older series with a particularly long follow-up period included 52 individuals with a confirmed urothelial papilloma. With an average follow-up of nearly ten years, few recurrent papillomas occurred; no invasive urothelial carcinomas were observed. Such rare conditions are often evaluated based on small retrospective series. The figures are therefore more useful for a general assessment than for a precise individual prognosis. Complete removal and a reliable diagnosis remain crucial prerequisites for the generalizability of these findings. [11]
Follow-up care tailored to the actual findings
Even in cases of inverted papillomas, carefully selected long-term follow-up series suggest a predominantly benign course. In a study of 75 cases without prior or concurrent urothelial carcinoma, one papilloma recurred; no subsequent carcinoma was detected. The authors therefore recommended monitoring as intensive as that used for Bladder cancer is not generally considered necessary. However, this does not imply a one-size-fits-all approach for all patients. Diagnostic certainty, complete removal, previous tumors, and the location within the urinary tract must all be taken into account. [10]
Ask for a specific follow-up plan. It should state whether and when another cystoscopy is scheduled, who will arrange it, and what symptoms would require an earlier appointment. Also ask whether the recommendation applies specifically to a benign papilloma or to a finding that is still unclear or additional. Regular checkups are easier to understand when their rationale and purpose are clearly stated.
After the procedure, you may experience temporary burning or traces of blood in your urine. Heavy or persistent bleeding, fever, severe pain, or an inability to urinate require immediate medical attention. Before you are discharged, ask for contact information for a healthcare provider you can reach. Your fluid intake, physical activity, and the resumption of anticoagulant medications should be tailored to your underlying medical conditions and the specific procedure you underwent. [8]
What You Should Know About Preventive Care
Smoking and exposure to certain occupational toxins are recognized risk factors for bladder cancer. However, this finding should not be automatically cited as an explanation for the development of a single benign papilloma. Quitting smoking and ensuring adequate occupational safety are nevertheless sensible health goals. If you have worked with relevant chemicals in your job, this Information as part of the urological medical history; it does not replace a histological diagnosis. [12]
Vitamin A supplements are not a reliable means of cancer prevention. The NIH patient information states that there is no evidence that vitamin A or beta-carotene supplements protect against cancer; high doses can be harmful. This is not a study specifically on papillomas, but it demonstrates why a general claim of protection from such dietary supplements is not justified. Targeted treatment of a confirmed deficiency is a separate matter and should be medically justified. [13]
For your next appointment, you can keep four points in mind: What is the final diagnosis? Was the lesion completely removed? Are there any additional changes? And what follow-up plan results from this? With these answers, a benign urothelial papilloma can be objectively classified without overlooking symptoms or prematurely adopting treatment measures intended for another condition.
A papilloma requires a different classification than a urothelial carcinoma
The terms "papilloma," "lesion with low malignant potential," and "urothelial carcinoma" describe different diagnoses. Their treatment and follow-up care are therefore not interchangeable. My article What is a biopsy? explains the diagnostic value of tissue. In cases of unclear, inconclusive findings, a second opinion from an experienced uropathologist may be helpful.[6]
The Classification of Bladder Cancer and Frequency Therapy In contrast, it treats malignant conditions. The measures taken in such cases must not be applied to a benign papilloma that has been completely removed without corresponding diagnostic findings. Conversely, a program list cannot confirm a benign diagnosis or replace a necessary endoscopy.
If blood in the urine disappears, this does not prove that the underlying cause has been eliminated. Symptoms may fluctuate regardless of the tissue findings. For any follow-up treatment, it should therefore be clear what the goal is and what further urological monitoring is planned. Have the final diagnosis, the completeness of the removal, and any possible additional changes documented in writing. New bleeding, fever, or difficulty urinating should be reevaluated, even if the previous findings were favorable.
Sources and Further Information
- WHO/IARC: Urinary and Male Genital Tumors, Classification Structure. Retrieved October 28, 2026.
- Genomic Landscape of Inverted Urothelial Papilloma and Urothelial Papilloma of the Bladder, 2019. Retrieved October 28, 2026.
- NIDDK: Hematuria, Blood in the Urine. Retrieved October 28, 2026.
- NIDDK: Cystoscopy and Ureteroscopy. Retrieved October 28, 2026.
- EAU Guidelines on Non-muscle-invasive Bladder Cancer 2026: Diagnosis. Retrieved October 28, 2026.
- Kitahama and Inamura: Inverted Urothelial Papilloma: Diagnostic Challenges and Clinical Implications, 2026. Retrieved October 28, 2026.
- RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma, 2024. Retrieved October 28, 2026.
- BAUS: Transurethral Telescopic Resection of a Bladder Tumor, Patient Information, March 2024. Retrieved October 28, 2026.
- Al Bashir et al.: Long-term Outcome of Primary Urothelial Papilloma, 2014. Retrieved October 28, 2026.
- Sung et al.: Natural History of Urothelial Inverted Papilloma, 2006. Retrieved October 28, 2026.
- Cheng et al.: Urothelial papilloma of the bladder: clinical and biological implications, 1999. Retrieved October 28, 2026.
- National Cancer Institute: Causes and Risk Factors for Bladder Cancer. Retrieved October 28, 2026.
- NIH Office of Dietary Supplements: Vitamin A and Carotenoids, Consumer. Retrieved October 28, 2026.
Topic Overview: Understanding Tumors.
Comments are closed, but trackbacks and pingbacks are open.